Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dextran sulfate-low molecular weight - TikoMed

Next Previous
Drug Profile

Dextran sulfate-low molecular weight - TikoMed

Alternative Names: Dextran sulfate sodium; DSSS5; IBsolvMIR; ILB®; LMW-DS; Low molecular weight dextran sulfate; TM-400; TM-500; TM-700

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TikoMed
  • Developer TikoMed; Uppsala University
  • Class Anti-inflammatories; Anticoagulants; Antiglaucomas; Antihyperglycaemics; Antihyperlipidaemics; Antivirals; Glucans; Neuroprotectants; Small molecules; Vascular disorder therapies
  • Mechanism of Action Blood coagulation factor inhibitors; Complement system protein inhibitors; Immunosuppressants; Intracellular signalling peptide and protein stimulants; Tumour necrosis factor alpha inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation; Pancreas transplant rejection
  • New Molecular Entity No
  • Available For Licensing Yes - Pancreas transplant rejection

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Motor neuron disease; Pancreas transplant rejection; Type 1 diabetes mellitus
  • Preclinical COVID 2019 infections
  • No development reported Glaucoma; Stem cell mobilisation; Stroke; Traumatic brain injuries

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for preclinical development in Glaucoma in Sweden (SC, Injection)
  • 28 Oct 2024 No recent reports of development identified for preclinical development in Stroke in Sweden (SC, Injection)
  • 28 Oct 2024 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in Sweden (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top